Safety of Pregabalin in the Treatment of Pain Due to Diabetic Peripheral Neuropathy
NCT00159731
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- Adults with Type 1 or 2 diabetes
- Patients must have pain in their lower legs or feet due to painful diabetic neuropathy that has lasted for at least 3 months
- Patients must not be in poor or unstable health.
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Mobile, Alabama
- Goodyear, Arizona
- Litchfield Park, Arizona
- Little Rock, Arkansas
- Fullerton, California
- Irvine, California
- La Jolla, California
- Boulder, Colorado
- Atlantis, Florida
- Bradenton, Florida
- Clearwater, Florida
- Destin, Florida
- Fort Walton Beach, Florida
- Hallandale Beach, Florida
- Palm Beach Gardens, Florida
- Sunrise, Florida
- West Palm Beach, Florida
- Decatur, Georgia
- Fort Wayne, Indiana
- Greenfield, Indiana
- Greenfirld, Indiana
- Lenexa, Kansas
- Hollywood, Maryland
- Ann Arbor, Michigan
- Nixa, Missouri
- Springfield, Missouri
- Missoula, Montana
- Asheville, North Carolina
- Dayton, Ohio
- Dayton, Ohio
- Toledo, Ohio
- Oklahoma City, Oklahoma
- Oklahoma, Oklahoma
- Greensburg, Pennsylvania
- Orangeburg, South Carolina
- Houston, Texas
- San Antonio, Texas
- San Antonio, Texas
- Salt Lake City, Utah
- Salt Lake City, Utah
- West Jordan, Utah
- Goodyear, Arizona
- Phoenix, Arizona
- Fresno, California
- Los Angeles, California
- Los Angeles, California
- Los Angeles, California
- Brandon, Florida
- Brandon, Florida
- Clearwater, Florida
- North Palm Beach, Florida
- Tampa, Florida
- West Palm Beach, Florida
- Winter Haven, Florida
- Columbus, Georgia
- Evansville, Indiana
- Wichita, Kansas
- Omaha, Nebraska
- Henderson, Nevada
- Las Vegas, Nevada
- Las Vegas, Nevada
- New York, New York
- Toledo, Ohio
- Oklahoma City, Oklahoma
- Oklahoma City, Oklahoma
- Medford, Oregon
- Portland, Oregon
- Portland, Oregon
- Altoona, Pennsylvania
- Duncansville, Pennsylvania
- Pawtucket, Rhode Island
- Orangeburg, South Carolina
- Houston, Texas
- Houston, Texas
- Norfolk, Virginia
- Brno-Bystrc,
- Praha 10,
- Praha 5,
- Johannesburg, Gauteng
- Lenasia, Gauteng
- Durban, Kwa-Zulu Natal
- Richards Bay,
- Falkoping,
- Malmo,
- Stockholm,
- Stockholm,
- Hot Springs, Arkansas
- La Jolla, California
- Torrance, California
- Torrance, California
- Denver, Colorado
- Ocala, Florida
- Ocala, Florida
- Palm Beach Gardens, Florida
- Sunrise, Florida
- West Palm Beach, Florida
- West Palm Beach, Florida
- Boston, Massachusetts
- Omaha, Nebraska
- Omaha, Nebraska
- Las Vegas, Nevada
- Englewood, New Jersey
- New Brunswick, New Jersey
- Albany, New York
- Rochester, New York
- Rochester, New York
- Greenville, North Carolina
- Toledo, Ohio
- Duncansville, Pennsylvania
- Dallas, Texas
- Dallas, Texas
- Houston, Texas
- San Antonio, Texas
- Salt Lake City, Utah
- Salt Lake City, Utah
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | Safety of Pregabalin in the Treatment of Pain Due to Diabetic Peripheral Neuropathy | |||
Official Title ICMJE | An Open Label Extension Safety Trial of Pregabalin (CI-1008) in Subjects With Diabetic Peripheral Neuropathy | |||
Brief Summary | The purpose of this study is to 1) provide continued pregabalin treatment for 6 additional months to patients who have taken part in the placebo controlled study A0081060; and 2) find out if pregabalin is safe at a dose of 600 mg/day (taken twice a day) | |||
Detailed Description | Not Provided | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 4 | |||
Study Design ICMJE | Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment | |||
Condition ICMJE | Diabetic Peripheral Neuropathy | |||
Intervention ICMJE | Drug: Pregabalin | |||
Study Arms ICMJE | Not Provided | |||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Completed | |||
Enrollment ICMJE | 160 | |||
Original Enrollment ICMJE | Same as current | |||
Study Completion Date ICMJE | May 2006 | |||
Primary Completion Date | Not Provided | |||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | United States | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT00159731 | |||
Other Study ID Numbers ICMJE | A0081036 | |||
Has Data Monitoring Committee | Not Provided | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Pfizer ( Pfizer's Upjohn has merged with Mylan to form Viatris Inc. ) | |||
Study Sponsor ICMJE | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | |||
Collaborators ICMJE | Not Provided | |||
Investigators ICMJE |
| |||
PRS Account | Pfizer | |||
Verification Date | July 2006 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |